文献速递睡眠呼吸障碍咽喉与嗓音

ADHERE注册研究:上气道刺激治疗OSA的疗效与预测因素

Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy.
PubMed 文献 · Laryngoscope · 2019-09-14

ADHERE是一项多中心前瞻性观察注册研究,纳入1017例CPAP治疗失败的OSA患者接受上气道刺激(UAS)治疗。12个月随访时AHI和Epworth嗜睡量表均显著改善,治疗使用时长每晚5.6±2.1小时;多因素分析中仅女性性别和较低基线BMI为疗效反应的显著预测因素。

要点

  • UAS可显著降低CPAP失败OSA患者的AHI并改善嗜睡,疗效持续至12个月。
  • 12个月治疗依从性高,每晚使用5.6±2.1小时。
  • 女性性别和较低基线BMI是12个月疗效反应的显著预测因素。

核心结论

  • UAS治疗在CPAP失败的OSA患者中持续显著改善主观和客观结局,疗效持久且依从性高。

研究设计与样本

  • 多中心前瞻性观察注册研究(ADHERE),2016年10月至2019年2月纳入1017例CPAP治疗失败的OSA患者。
  • 640例完成6个月随访,382例完成12个月随访;基线、植入、滴定后6个月和12个月收集人口学与睡眠监测数据。

主要发现

  • 12个月时中位AHI从32.8(IQR 23.6-45.0)降至9.5(IQR 4.0-18.5),均值从35.8±15.4降至14.2±15.0,P < .0001。
  • Epworth嗜睡量表从11.0(IQR 7-16)改善至7.0(IQR 4-11),均值从11.4±5.6降至7.2±4.8,P < .0001。
  • 12个月时治疗使用时长每晚5.6±2.1小时。
  • 多因素模型中仅女性性别和较低基线BMI为12个月疗效反应的显著预测因素。

关键数值与推荐

  • 疗效反应定义为12个月访视时AHI下降≥50%且AHI≤20。

临床怎么用

  • UAS可作为CPAP失败OSA患者的有效治疗选择,尤其需关注女性性别和较低基线BMI等预测因素。
  • 高治疗依从性支持UAS的长期应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/HYPOTHESIS: The ADHERE Registry is a multicenter prospective observational study following outcomes of upper airway stimulation (UAS) therapy in patients who have failed continuous positive airway pressure therapy for obstructive sleep apnea (OSA). The aim of this registry and purpose of this article were to examine the outcomes of patients receiving UAS for treatment of OSA. STUDY DESIGN: Cohort Study. METHODS: Demographic and sleep study data collection occurred at baseline, implantation visit, post-titration (6 months), and final visit (12 months). Patient and physician reported outcomes were also collected. Post hoc univariate and multivariate analysis was used to identify predictors of therapy response, defined as ≥50% decrease in Apnea-Hypopnea Index (AHI) and AHI ≤20 at the 12-month visit. RESULTS: The registry has enrolled 1,017 patients from October 2016 through February 2019. Thus far, 640 patients have completed their 6-month follow-up and 382 have completed the 12-month follow-up. After 12 months, median AHI was reduced from 32.8 (interquartile range [IQR], 23.6-45.0) to 9.5 (IQR, 4.0-18.5); mean, 35.8 ± 15.4 to 14.2 ± 15.0, P < .0001. Epworth Sleepiness Scale was similarly improved from 11.0 (IQR, 7-16) to 7.0 (IQR, 4-11); mean, 11.4 ± 5.6 to 7.2 ± 4.8, P < .0001. Therapy usage was 5.6 ± 2.1 hours per night after 12 months. In a multivariate model, only female sex and lower baseline body mass index remained as significant predictors of therapy response. CONCLUSIONS: Across a multi-institutional study, UAS therapy continues to show significant improvement in subjective and objective OSA outcomes. This analysis shows that the therapy effect is durable and adherence is high. LEVEL OF EVIDENCE: 2 Laryngoscope, 130:1333-1338, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Thaler E, Schwab R, Maurer J, et al. Results of the ADHERE upper airway stimulation registry and predictors of therapy efficacy. Laryngoscope. 2019. PMID: 31520484. doi:10.1002/lary.28286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。